INV-043 injection / Invion, Hanlim Pharma - LARVOL DELTA

Life sciences company Invion Group…and Korean partner Hanlim Pharm Co Ltd will invest in the non-clinical research required to support an Australian trial of intravenously administered HL270 (INV043) for the treatment of esophageal cancer. (Small Caps) - "The $2 million two-stage work program will commence with efficacy studies to demonstrate the drug’s impact on oesophageal cancer in animal models ahead of preparations for the first-in-human trial including non-clinical studies to assess stability and toxicity and the submission of a clinical trial notification to the Therapeutic Goods Administration."

Financing • Esophageal Cancer

Invion Limited…has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its lead drug candidate, INV043, for the treatment of anal cancer. (finnewsnetwork)

Orphan drug • Anal Carcinoma

Invion advances skin cancer treatment with positive safety data for INV043 in Phase I/II trial (Small Caps) - P1/2 | N=NA | "Invion...has reported no adverse events from the application and use of its lead drug candidate INV043 on the first six patients of a Phase I/II non-melanoma skin cancer (NMSC) trial in Queensland....Patients also gave early indications of responding positively to the drug, with an observable reduction in NMSC lesion size at 15 days and 30 days after a single treatment cycle."

P1/2 data • Non-melanoma Skin Cancer